Drug Combination in Clinical Cancer Treatments

Title:Drug Combination in Clinical Cancer Treatments

Volume: 12 Issue: 3

Author(s): Da-Yong Lu*, Ting-Ren Lu, Nagendra Sastry Yarla, Hong-Ying Wu, Bin Xu, Jian Ding and Hong Zhu

Affiliation:

• School of Life Sciences, Shanghai University, Shanghai 200444,China

Keywords: Biotherapy, cancer stem cell, drug combination, drug resistance, neoplasm metastasis, personalized cancer therapy.

Abstract: Aim: The modality of anticancer drug combinations needs to be renovated from empirical into technical-supportive systems.

Methods: To challenge past therapeutic routines, the new landscape may be established. Among the different areas of anticancer drug combination study, research in the fields of medical study is the most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/ molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data analysis, therapeutic toxicity monitor, personalized cancer medicine and so on.

Discussion: This article addresses these types of cancer therapeutic management systems for clinical anticancer drug combination utilities.

Conclusion: Future cancer drug combinational studies and clinical optimums must be implemented.

Cite this article as:

Lu Da-Yong*, Lu Ting-Ren , Yarla Sastry Nagendra , Wu Hong-Ying , Xu Bin , Ding Jian and Zhu Hong , Drug Combination in Clinical Cancer Treatments, Reviews on Recent Clinical Trials 2017; 12 (3) . https://dx.doi.org/10.2174/1574887112666170803145955